Wyss Institute

Pluto Biosciences Raises $3.7M to Revolutionize Biological Data Interpretation and Accelerate Life Sciences Discoveries

Retrieved on: 
星期二, 五月 2, 2023
Technology, Research, Health Technology, Software, Biotechnology, Health, Data Management, Other Science, Science, Computational biology, Data management, CRISPR, Software as a service, Harvard University, Partner, RNA-Seq, General partnership, Silverton Partners, Doctor of Philosophy, Proteomics, RUN, Organization, CO, Running, Metabolomics, Wyss Institute, Drug discovery, Growth, Wyss Institute for Biologically Inspired Engineering, Silverton, CUT, Pharmaceutical industry, Renewable energy, Pluto

Pluto Biosciences , a cutting-edge life sciences software-as-a-service (SaaS) platform, announced today the closing of a $3.7 million seed round led by Silverton Partners in Austin, TX.

Key Points: 
  • Pluto Biosciences , a cutting-edge life sciences software-as-a-service (SaaS) platform, announced today the closing of a $3.7 million seed round led by Silverton Partners in Austin, TX.
  • With its biology-focused user experience, Pluto offers flexibility and ease-of-use when running bioinformatics analyses and creating plots, allowing researchers to focus on making groundbreaking discoveries and presenting them for maximum impact.
  • Powers is confident that the investment will accelerate Pluto's growth and enable the Company to reach even more organizations in the life sciences industry.
  • Scientists currently use Pluto to accelerate biological applications spanning from preclinical and translational science research, to cell and gene therapies, drug discovery and development, and clinical research.

Lifespin Announces Inaugural Membership in the Industrial Participant Program of the Wyss Diagnostics Accelerator at Harvard University

Retrieved on: 
星期四, 四月 20, 2023
Software, Research, General Health, Mobile, Wireless, Data Management, Apps, Applications, Technology, Medical Devices, Artificial Intelligence, Health Technology, Science, Health, Other Science, Yale University, Software as a service, CT, Obesity, Therapeutic drug monitoring, Diabetes, Engineering, NMR, Cone Health Women's Hospital, Inflammation, Metabolomics, DSM-IV codes, A.I, Risk, Biomarker, Harvard University, Metabolome, Wyss Institute for Biologically Inspired Engineering, IPP, RUO, Cell biology, Metabolism, Pathology, Patient, Wyss Institute, Cancer, Artificial intelligence, Hospital, Wyss, Neurology, Disease, Medical device, Medical imaging

Lifespin GmbH, based in Regensburg with offices in Boston, Massachusetts, announced today that it is one of 24 inaugural members of the Wyss Institute for Biologically Inspired Engineering at Harvard University’s Diagnostics Accelerator ( Wyss DxA ) Industrial Participant Program (IPP).

Key Points: 
  • Lifespin GmbH, based in Regensburg with offices in Boston, Massachusetts, announced today that it is one of 24 inaugural members of the Wyss Institute for Biologically Inspired Engineering at Harvard University’s Diagnostics Accelerator ( Wyss DxA ) Industrial Participant Program (IPP).
  • Originally formed in 2021 as a pilot program, the IPP recently has transitioned from its pilot phase into an official program within the Harvard system, and consolidated its base of initial industrial partners, including Lifespin.
  • “The mission of the Wyss DxA is to get transformative diagnostic tests to market and reduce disease burden for patients with major unmet needs.
  • Lifespin ( www.lifespin.health ) is a deep data company that seeks to detect distinct deviations in the human metabolism caused by diseases.

FitBiomics to Make Fatigue Obsolete, Provides Early Access Opportunity to Lactic Acid Metabolizer, Veillonella

Retrieved on: 
星期二, 四月 18, 2023
Midnight, Mobile Suit Gundam, Nature Medicine, Engineering, Lactic acid, Research, Harvard University, Doctor of Philosophy, Harvard Fatigue Laboratory, Wyss Institute for Biologically Inspired Engineering, Wyss Institute, Longevity, Health, VIP, Fatigue, Pharmaceutical industry, Dietary supplement, Veillonella

NEW YORK, April 18, 2023 /PRNewswire/ -- FitBiomics, a leading biotechnology organization using microbiome innovation to enhance human health and performance, has announced successful translation of Veillonella. Veillonella is a first-of-its-kind, next-generation probiotic that naturally converts lactic acid into energy to fight fatigue and promote endurance. To celebrate this achievement and accelerate commercial optimization of Veillonella, FitBiomics opened applications for Project V - an early access opportunity to try Veillonella.

Key Points: 
  • Veillonella is a first-of-its-kind, next-generation probiotic that naturally converts lactic acid into energy to fight fatigue and promote endurance.
  • To celebrate this achievement and accelerate commercial optimization of Veillonella, FitBiomics opened applications for Project V - an early access opportunity to try Veillonella.
  • FitBiomics plans to bring Veillonella, a discovery first published in Nature Medicine in 2019, to market before the end of the year.
  • Veillonella, along with Nella, the initial product from FitBiomics, are patented probiotic strains that go beyond gut health and provide holistic health benefits.

Wyss Institute’s Lab-on-a-Molecule Drug Discovery Project Receives Funding from Northpond Labs

Retrieved on: 
星期二, 四月 4, 2023
Molecule, CFA, Boston University, Associate, Protein, Hospital, Patient, Wyss Institute, Environment, Laboratory, Disease, Heart, University, Pediatrics, Therapy, Research, Innovation, Drug discovery, Massachusetts General Hospital, Spaulding Rehabilitation Hospital, Tufts University, DNA, Harvard University, MIT, Massachusetts Institute of Technology, Wyss, Berlin, Wyss Institute for Biologically Inspired Engineering, Biochemistry, Partnership, Beth Israel Deaconess Medical Center, INSERT, Woman, RNA, Priscilla Chan, Harvard Medical School, Molecular medicine, Biological engineering, Science, Pharmacology, Medtech, Pharmaceutical industry, Vaccine, Design, Brigham, Engineering

This is the third Wyss project to which Northpond Labs has provided funding and in-kind support to ensure a pathway toward rapid technology commercialization.

Key Points: 
  • This is the third Wyss project to which Northpond Labs has provided funding and in-kind support to ensure a pathway toward rapid technology commercialization.
  • In 2020, the Wyss Institute, Northpond Labs and other collaborating institutions launched the Laboratory for Bioengineering Research and Innovation at the Wyss Institute as part of a research collaboration.
  • In 2022, the Institute, in partnership with Northpond Labs, spun out EnPlusOne Biosciences, an RNA solutions company which started as a controlled enzymatic RNA synthesis project funded by Northpond Labs in 2020.
  • Because of its potential as a next-generation drug discovery technology, the Lab-on-a-Molecule project had already been selected by the Wyss Institute as one of its 2022 Validation Projects .

David Weitz, Renowned Harvard Professor, Joins ClexBio Scientific Advisory Board

Retrieved on: 
星期三, 四月 5, 2023
Health, Clinical Trials, Research, Pharmaceutical, Science, Biotechnology, National academy, Harvard University, National Academy of Engineering, Applied physics, Quality of life, Coronavirus Scientific Advisory Board, American Academy, Wyss Institute for Biologically Inspired Engineering, Regenerative medicine, Microfluidics, Professor, CLEX, Patient, Biophysics, Wyss Institute, Physics, Knowledge, Entrepreneurship, Management, Pharmaceutical industry, Engineering

ClexBio, an innovative regenerative medicine company focused on developing next-generation bioengineered implants, is proud to announce the appointment of Professor David Weitz to its Scientific Advisory Board.

Key Points: 
  • ClexBio, an innovative regenerative medicine company focused on developing next-generation bioengineered implants, is proud to announce the appointment of Professor David Weitz to its Scientific Advisory Board.
  • Prof. Weitz expressed his excitement about joining the ClexBio team, stating, "I am thrilled to be joining the Scientific Advisory Board of ClexBio.
  • Armend Håti, CEO and Co-Founder of ClexBio, welcomed Prof. Weitz with enthusiasm, saying, "We are honored to have Prof. David Weitz join our Scientific Advisory Board.
  • The addition of Prof. Weitz to the Scientific Advisory Board further solidifies ClexBio's commitment to pushing the boundaries of scientific innovation and delivering transformative healthcare solutions.

Amend Surgical Receives Funding for Suture-less Nerve Repair Device

Retrieved on: 
星期二, 四月 11, 2023
SpaceTEC National Resource Center for Aerospace Technical Education, Tissue, Partnership, Commercialization, Connective tissue, University, Nerve, Marketing, Harvard University, Elective surgery, ITP, Spine, DOC, Research, Private practice, Sympathetic nervous system, Bangladesh Technical Education Board, Regenerative medicine, National Institute of Dental and Craniofacial Research, Regeneration, Motion, Wyss Institute, NIDCR, Collagen, OEM, FDA, Trauma, Wyss Institute for Biologically Inspired Engineering, Pharmaceutical industry, Dentistry

ALACHUA, Fla., April 11, 2023 /PRNewswire/ -- Amend Surgical, Inc., an Alachua-based medical device company, announced today that it has been awarded a substantial product development funding from The Michigan-Pittsburgh-Wyss Regenerative Medicine (MPWRM) Resource Center to commercialize a novel, suture-less solution for the repair of peripheral nerves. Tissure is a resorbable hydrogel membrane with a chitosan-based adhesive that has the adhesion and mechanical strength to potentially replace suture for the repair of peripheral nerve injuries. Tissure is easy to apply and will greatly simplify this challenging surgical procedure. Amend Surgical exclusively licensed the rights for this technology from the Wyss Institute at Harvard University in 2020.

Key Points: 
  • Amend Surgical exclusively licensed the rights for this technology from the Wyss Institute at Harvard University in 2020.
  • The use of suture to repair peripheral nerve injuries is the current standard of care.
  • Eliminating suture for peripheral nerve repair avoids this trauma, can decrease intervening scar tissue, and protect the repair site.
  • Amend Surgical currently has nine employees and occupies a manufacturing and administrative space in the biotech corridor of Alachua, Florida.

Center for Contemporary Sciences Launches the SPARK Pledge to Modernize Safety and Toxicity Testing

Retrieved on: 
星期二, 三月 28, 2023
Partnership, European Parliament, European, Pledge, Toxicity, Research, Household, Bethanie Mattek-Sands, Organization, Corteva, Animal, United States Environmental Protection Agency, SPARK, Wyss Institute, Lush, CCS, Health, FDA, Therapy, Wyss Institute for Biologically Inspired Engineering, Pharmaceutical industry

GAITHERSBURG, Md., March 28, 2023 /PRNewswire/ -- Center for Contemporary Sciences (CCS) announces a new pledge campaign to advance human health and environmental protection.

Key Points: 
  • GAITHERSBURG, Md., March 28, 2023 /PRNewswire/ -- Center for Contemporary Sciences (CCS) announces a new pledge campaign to advance human health and environmental protection.
  • The SPARK Pledge is a commitment by industry and scientific entities to replace the use of ineffective and harmful animal experimentation in toxicity and safety testing with modern, more effective solutions.
  • "The Lush Prize welcomes the launch of the SPARK pledge led by the Center for Contemporary Sciences and is very pleased to co-sponsor the initiative.
  • "MatTek joined the SPARK Pledge because our core value is modernizing safety testing with advanced science, and we believe that the future of human health depends on it."

Sherlock at Apex of CRISPR-based Diagnostics after USPTO Grants Earliest Priority Patent

Retrieved on: 
星期二, 二月 21, 2023
DNA, Wyss Institute for Biologically Inspired Engineering, State, Patent, Gene editing, Wyss Institute, Synthetic biology, Therapy, Broad Institute, Biology, Tolo, Tuberculosis, Sherlock Biosciences, Acquisition, CRISPR, Sherlock, RNA, Dicarboxylic acid, IP, COVID-19, Malaria, Pharmaceutical industry, Vaccine

WATERTOWN, Mass., Feb. 21, 2023 /PRNewswire/ -- Sherlock Biosciences, a company engineering biology to bring next-generation lab-quality diagnostic testing to the point of need, today announced that the U.S. Patent and Trademark Office (USPTO) has granted a patent for the diagnostic use of the Cas12 enzyme, establishing Sherlock as the leader in CRISPR-based diagnostics with freedom to operate in the U.S. Sherlock has exclusive U.S. rights to the patent from Shanghai-based Tolo Biotech, plus additional intellectual property (IP) for Cas12 and Cas13 from the Broad Institute, giving the company the preeminent IP position in the space.

Key Points: 
  • The newly granted patent covers a method for detecting nucleic acids leveraging the collateral cleavage activity of Cas12.
  • Sherlock and its academic co-founders have already demonstrated the potential for flexible, high-accuracy, low-cost Cas12-based detection of diseases, including malaria, tuberculosis and COVID-19.
  • Sherlock's CRISPR-based diagnostics rely on a key pair of technologies to detect diseases, covered by the patent: amplification and collateral cleavage.
  • "With this patent, Sherlock has a clear, unimpeded pathway to commercialization for our CRISPR-based diagnostics," said Jim Collins, Ph.D., co-founder and board member of Sherlock Biosciences.

EnPlusOne Biosciences Expands Scientific Advisory Board

Retrieved on: 
星期三, 二月 8, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Genetics, Gene editing, Middle States Commission on Higher Education, Wyss Institute, Defence Scientific Advisory Council, MIT, ALS, Young, Therapy, Dalhousie University, Harvard University, Harvard–MIT Program in Health Sciences and Technology, Biochemistry, Editorial, McGill University, Nucleic acid, Angel Award, RNA, George Church, United States Air Force Scientific Advisory Board, Harvard Medical School, Engineering, University, Wyss Institute for Biologically Inspired Engineering, Nucleic Acids Research, Oligonucleotide, Gene silencing, Outline of health sciences, Knowledge, OTS, Disease, Bachelor of Science, University of Massachusetts Chan Medical School, Angel, University of Massachusetts, Enzyme, Wyss, Doctor of Philosophy, Fine chemical, Management, Chemistry

EnPlusOne Biosciences, Inc. , a biotechnology company harnessing the power of enzymes to synthesize RNA oligonucleotides, today announced that Jonathan K. Watts, Ph.D., Professor, RNA Therapeutics Institute and Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Chan Medical School, has been appointed to the company’s Scientific Advisory Board.

Key Points: 
  • EnPlusOne Biosciences, Inc. , a biotechnology company harnessing the power of enzymes to synthesize RNA oligonucleotides, today announced that Jonathan K. Watts, Ph.D., Professor, RNA Therapeutics Institute and Department of Biochemistry and Molecular Pharmacology, University of Massachusetts Chan Medical School, has been appointed to the company’s Scientific Advisory Board.
  • Dr. Watts, who was also a member of the Board of Directors of the Oligonucleotide Therapeutics Society (OTS) from 2015 to 2021, is a highly regarded scientific investigator in the oligonucleotide field.
  • Daniel Wiegand, MSChE, CEO of EnPlusOne said, “We are delighted to attract an experienced, respected researcher like Jon to our Scientific Advisory Board.
  • He serves on the Editorial Boards of Nucleic Acid Therapeutics and Nucleic Acids Research in addition to the Scientific Advisory Council of the OTS.

Spear Bio expands NAB-Sure™ Assays to Support Study of SARS-CoV-2 Variants

Retrieved on: 
星期二, 一月 3, 2023
Harvard University, Severe acute respiratory syndrome coronavirus 2, Infection, Public health surveillance, Wyss Institute for Biologically Inspired Engineering, Lance, Serology, COVID-19, DBS, Plasma, Serum, Area studies, PCR, Vaccine, Wyss Institute, Research

WOBURN, Mass., Jan. 3, 2023 /PRNewswire/ -- Spear Bio is expanding its NAB-Sure™ Neutralizing Antibody Test Kit product line with current SARS-CoV-2 variants.

Key Points: 
  • WOBURN, Mass., Jan. 3, 2023 /PRNewswire/ -- Spear Bio is expanding its NAB-Sure™ Neutralizing Antibody Test Kit product line with current SARS-CoV-2 variants.
  • This addresses the need of researchers and vaccine developers faced with emerging SARS-CoV-2 variants as they continue to study immune responses to COVID-19 and protection durability of vaccines.
  • Earlier this year Spear Bio introduced NAB-Sure™, a cell-free assay, which uses real-time PCR systems to quantify neutralizing antibodies (NAbs) from plasma, serum, or dried blood spot (DBS) samples.
  • This is key to understanding the immune response to vaccines and infection," said Jerome Clavel, CEO of Spear Bio.